Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 + Irinotecan + Bevacizumab in mCRC
NCT06202001Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in metastatic colorectal cancer (mCRC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Oct 2022; status: recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06202001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202001.